Source: Annual Congress 2001 - Inflammation, infection and exercise capacity in cystic fibrosis patients
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Camargos, I. Assis, F. Reis, N. Sulmonett, A. Carneiro (Belo Horizonte, Brazil). Revisiting FEV1 in cystic fibrosis. Eur Respir J 2001; 16: Suppl. 31, 862

Member's Comments

No comment yet.

Related content which might interest you: Exercise capacity in patients with cystic fibrosis vs non-cystic fibrosis bronchiectasis Source: International Congress 2018 – Mechanisms that underlie exercise limitation in various respiratory diseases Year: 2018 Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis Source: Eur Respir J 2012; 40: 61-66 Year: 2012 Cystic fibrosis fibrosis bronchiectasis Source: Virtual Congress 2020 – Paediatric year in review Year: 2020 Neomacrolides in cystic fibrosis Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease Year: 2012 Dynamic hyperinflation in cystic fibrosis Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Longitudinal decline in FEV1 in an adult non-cystic fibrosis bronchiectasis cohort Source: Eur Respir J 2007; 30: Suppl. 51, 529s Year: 2007 Diagnosing bronchiectasis and cystic fibrosis Source: International Congress 2018 – ME8 Diagnosing bronchiectasis and cystic fibrosis Year: 2018 Lung clearance index predicts pulmonary exacerbations in cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Airway clearance techniques in cystic fibrosis Source: Eur Respir J 2006; 27: 1082-1083 Year: 2006 Airway inflammation in cystic fibrosis Source: Eur Respir Monogr 2014; 64: 14-31 Year: 2014 Exercise in cystic fibrosis Source: Eur Respir Monogr 2014; 64: 203-218 Year: 2014 Improving airway clearance in cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 169-187 Year: 2014 Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis Source: Eur Respir J 2007; 30: Suppl. 51, 528s Year: 2007 Global impact of bronchiectasis and cystic fibrosis Source: Breathe 2016; 12: 222-235 Year: 2016 Relationship between airflow limitation and lung volume in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 301s Year: 2002 Exercise improvements in ivacaftor treated G551D cystic fibrosis patients are not solely related to FEV1 and sweat changes Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 Non-cystic fibrosis bronchiectasis Source: International Congress 2019 – Recent clinical advances in inhalation therapy Year: 2019 Non-cystic fibrosis bronchiectasis Source: Virtual Congress 2020 – Paediatric year in review Year: 2020 Non-cystic fibrosis bronchiectasis Source: Eur Respir Monogr 2017; 77: 38-57 Year: 2017 Immuno-allertypes in non-cystic fibrosis  bronchiectasis Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018